DAPIPRAZOLE HYDROCHLORIDE
LOE Approachingdapiprazole hydrochloride
NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dapiprazole hydrochloride is an alpha-adrenergic antagonist ophthalmic solution approved in 1990 for reversal of pharmacologic mydriasis (pupil dilation). It works by blocking alpha-1 adrenergic receptors in the iris, causing pupil constriction. The drug is indicated for patients who require restoration of normal pupil function after diagnostic or surgical procedures.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30 percentile), indicating potential for team restructuring and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, stable lifecycle stage with minimal hiring activity. Career opportunities on this brand are limited and focused on operational efficiency rather than growth-oriented initiatives.
Brand ManagerCommercial Operations Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.